Autolus Therapeutics plc
NASDAQ:AUTLBiotechnology
+$0.01 today
- Market cap
- $282.13M
- Beta
- 2.01
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.09
Volume 2.56M
Average 1.60M
AUTL Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Autolus Therapeutics plcNASDAQ: AUTL
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense declines year over year
Q1 FY2026 income tax expense of $861.55K fell 61.3% year over year, ahead of the -83.8% change in trailing-twelve-month income tax expense.
Context
- Income tax expense amounted to 11.4% of revenue in FY2025, down 3.7 pp from a year earlier.
- Income tax expense increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -61.3% holds above the trailing-twelve-month pace of -83.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- (8.65M) USD
- Year-over-year change
- -666.0%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.65M) | -666.0% |
| FY2024 | 2024-12-31 | 1.53M | +8142.1% |
| FY2023 | 2023-12-31 | (19K) | -107.0% |
| FY2022 | 2022-12-31 | 272K | +369.0% |
| FY2021 | 2021-12-31 | 58K | — |
Income Tax Expense vs competitors
How AUTL compares with its peers on the latest reported figures
- AUTL's LTM Mar 2026 income tax expense of $609.26K is the 2nd highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -83.8% is the 3rd highest of 7, against a peer median of -101.9%.
- Income tax expense amounts to 0.7% of revenue for AUTL, versus a peer median of 0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.42M | +88.3% | +183.2% | 2.4% | |
| LTM Mar 2026 | $609.26K | -83.8% | — | 0.7% | |
| LTM Mar 2026 | $31K | +186.1% | +37.2% | 0.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | -$68K | -103.8% | — | — | |
| LTM Mar 2026 | -$550K | -6011.1% | — | 4.9% | |
| LTM Mar 2026 | -$2.16M | -919.5% | — | 3.2% | |
| Peer median (excluding AUTL) | $0 | -101.9% | +110.2% | 0.1% | |
Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.51M | 6.19M | 1.7M | 10.12M | 75.56M |
| Cost of Revenue | 0 | 0 | 0 | 141.02M | 96.59M |
| Gross Profit | 1.51M | 6.19M | 1.7M | (130.9M) | (21.03M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | -1293.5% | -27.8% |
| Research & Development | 110.84M | 117.35M | 130.48M | 158.14M | 128.59M |
| Selling, General & Admin | 31.87M | 31.9M | 46.75M | 0 | 131.82M |
| Operating Expenses | 141.88M | 149.09M | 181.4M | 110.53M | 260.41M |
| Depreciation & Amortization | 8.46M | 7.42M | 6.57M | 7.72M | 9.84M |
| EBITDA | (132.48M) | (132.24M) | (156.77M) | (233.07M) | (250.26M) |
| EBITDA Margin | -8790.6% | -2135.0% | -9232.6% | -2303.1% | -331.2% |
| Operating Income | (140.37M) | (142.89M) | (179.7M) | (241.43M) | (281.44M) |
| Operating Margin | -9314.8% | -2307.0% | -10583.1% | -2385.6% | -372.4% |
| Interest Income | 262K | 1.71M | 13.51M | 32.36M | 19.02M |
| Interest Expense | 1.11M | 8.91M | 45.07M | 9.29M | 36.76M |
| Other Income / Expenses | (1.66M) | (5.67M) | (28.7M) | 22.29M | (15.41M) |
| Income Before Tax | (142.04M) | (148.57M) | (208.4M) | (219.13M) | (296.85M) |
| Pre-Tax Margin | -9425.2% | -2398.6% | -12273.4% | -2165.4% | -392.8% |
| Income Tax Expense | 58K | 272K | (19K) | 1.53M | (8.65M) |
| Net Income | (142.1M) | (148.84M) | (208.38M) | (220.66M) | (288.2M) |
| Net Margin | -9429.1% | -2403.0% | -12272.3% | -2180.5% | -381.4% |
| EPS (Basic) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| EPS (Diluted) | (1.97) | (1.57) | (1.20) | (0.87) | (1.08) |
| Weighted Avg Shares | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
| Weighted Avg Shares (Diluted) | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M |
Autolus Therapeutics plc
NASDAQ:AUTL
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.